Scilex Holding (SCLXW) Total Non-Current Liabilities (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Total Non-Current Liabilities of $522.2 million in Q1 2026, down 9.43% quarter-over-quarter from $576.6 million in Q4 2025, and up 121.57% on a YoY basis from $235.7 million in Q1 2025.
Scilex Holding (SCLXW) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Scilex Holding's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $522.2 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 121.57% year-over-year to $522.2 million; the TTM figure through Mar 2026 stood at $522.2 million (up 121.57% YoY), while the FY2025 annual figure was $576.6 million, up 102.59% from the prior year.
- Total Non-Current Liabilities was $522.2 million for Q1 2026 at Scilex Holding, down from $576.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $576.6 million in Q4 2025 to a low of $11.0 million in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $237.2 million across 5 years, with a median of $272.7 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities sank 81.57% in 2022, then jumped 2090.64% in 2023.
- A 5-year view of Total Non-Current Liabilities shows it stood at $49.1 million in 2022, then jumped by 455.94% to $272.7 million in 2023, then increased by 4.35% to $284.6 million in 2024, then soared by 102.59% to $576.6 million in 2025, then dropped by 9.43% to $522.2 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $522.2 million (Q1 2026), $576.6 million (Q4 2025), and $373.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -31.03 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 522.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 522.16 Mn |
| Dec 31, 2025 | 576.56 Mn |
| Sep 30, 2025 | 373.62 Mn |
| Jun 30, 2025 | 332.58 Mn |
| Mar 31, 2025 | 235.67 Mn |
| Dec 31, 2024 | 284.59 Mn |
| Sep 30, 2024 | 300.29 Mn |
| Jun 30, 2024 | 319.05 Mn |
| Mar 31, 2024 | 274.09 Mn |
| Dec 31, 2023 | 272.73 Mn |
| Sep 30, 2023 | 241.10 Mn |
| Jun 30, 2023 | 109.48 Mn |
| Mar 31, 2023 | 68.49 Mn |
| Dec 31, 2022 | 49.06 Mn |
| Sep 30, 2022 | 11.01 Mn |
| Jun 30, 2022 | 51.65 Mn |
| Mar 31, 2022 | 11.02 Mn |
| Dec 31, 2021 | 266.11 Mn |
| Sep 30, 2021 | 5.23 Mn |
| Jun 30, 2021 | 5.21 Mn |